Bezlotoxumab Brand Name– ZINPLAVA
What is Bezlotoxumab
Bezlotoxumab is a human monoclonal antibody that binds to Clostridium difficile toxin B that is used to reduce recurrence of C. difficile infection (CDI) in adults who are receiving antibacterial treatment of CDI and are at a high risk for CDI recurrence.
Bezlotoxumab is not an antibacterial drug; it is only for use in conjunction with appropriate antibacterial agents.
Bezlotoxumab was FDA-approved in October 2016.
Indications
- Clostridium difficile
- pseudomembranous colitis
Side Effects
- antibody formation
- dizziness
- dyspnea
- fatigue
- fever
- headache
- heart failure
- hypertension
- infusion-related reactions
- nausea
- ventricular tachycardia
Monitoring Parameters
- laboratory monitoring not necessary
Contraindications
- breast-feeding
- heart failure
- pregnancy
Interactions
There are no drug interactions associated with Bezlotoxumab products.
